

Updated data from SNT-5505 myelofibrosis Phase 2 study to be presented at EHA2025

Syntara Limited (ASX:SNT), a clinical-stage drug development company, is pleased to announce that its abstract has been selected for a poster presentation at the European Hematology Association 2025 Congress (EHA2025). The presentation will contain the next data update from the ongoing Phase 2 trial evaluating SNT-5505 in combination with ruxolitinib to treat the bone marrow cancer myelofibrosis.

Syntara's abstract, titled 'A PHASE 1/2A TRIAL OF PXS-5505, A NOVEL PAN-LYSYL OXIDASE INHIBITOR, IN PATIENTS WITH ADVANCED MYELOFIBROSIS', will be presented in Poster Session 2 at **18:30 – 19:30 CEST, Saturday 14 June (02:30 – 03:30 AEST, Sunday 15 June)**.

The 30th EHA Congress is being held in Milan, Italy from 12-15 June 2025, and is a highly regarded forum for original data, haematological innovation and evidence-based knowledge of primary clinical relevance.

Syntara CEO Gary Phillips said: "We're proud to see SNT-5505 selected for a poster presentation at one of the premier haematology events worldwide in the EHA2025 Congress. This highlights the growing recognition of the potential impact of this program, following strong early data presented at ASH2024. The timing of the conference aligns well with the company receiving a substantial amount of additional data from the ongoing myelofibrosis trial and facilitates peer review by the world's leading haematologists. We look forward to bringing the update to shareholders at the same time."

It should be noted that while abstracts for the EHA2025 Congress will be published on 14 May 2025, the abstract relevant to Syntara's SNT-5505 will only describe the study and will not contain the new data. The new data will only be presented at the time of the event, while being announced to the ASX within its continuous disclosure obligations.

#ENDS#

SOURCE:

Syntara Limited (ASX: SNT),
Sydney, Australia
(ABN: 75 082 811 630)

AUTHORISED FOR RELEASE TO ASX BY:

Syntara Limited Disclosure Committee.

CONTACT:**Syntara investor / media relations:**

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

JOIN THE SYNTARA MAILING LIST [HERE](#)





About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. SNT-5505 has already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. After encouraging phase 2a trial results when used as a monotherapy in myelofibrosis, SNT-5505 is now being studied with a JAK inhibitor in a suboptimal response setting. Protocols for another two phase 1c/2 studies with SNT-5505 in patients with a blood cancer called myelodysplastic syndrome are in development and expected to commence recruitment by H1 2025.

Syntara is also advancing topical pan-LOX inhibitors in scar prevention and scar modification programs as part of an ongoing collaboration with Professor Fiona Wood and the University of Western Australia. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAO-B inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, MASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol® - a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. www.syntaraTX.com.au.

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.